318 related articles for article (PubMed ID: 10481111)
21. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
22. [The value of tumor markers in colorectal cancer].
Peters KM; Grundmann R
Leber Magen Darm; 1989 Jan; 19(1):18-25. PubMed ID: 2927234
[TBL] [Abstract][Full Text] [Related]
23. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer.
Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Carone MD; Aloe S; Tedesco M; Mancini R; Casale V; Carlini S; Casciani CU; Roselli M; Guadagni F
Anticancer Res; 1999; 19(2B):1363-8. PubMed ID: 10365107
[TBL] [Abstract][Full Text] [Related]
25. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
26. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
27. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study.
Yüceyar S; Ertürk S; Dirican A; Cengiz A; Saner H
Int Surg; 1996; 81(2):136-9. PubMed ID: 8912078
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
[TBL] [Abstract][Full Text] [Related]
29. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
30. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
31. [The pre- and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma].
Iarŭmov N; Ignatov A; Viiachki I
Khirurgiia (Sofiia); 1998; 51(3):42-8. PubMed ID: 9974027
[TBL] [Abstract][Full Text] [Related]
32. [Measurement of serum protein-bound hexose--an aid in the diagnosis and after-care of colorectal cancers?].
Putzki H; Reichert B; Hue M
Zentralbl Chir; 1992; 117(6):331-3. PubMed ID: 1519392
[TBL] [Abstract][Full Text] [Related]
33. Estimating the probability of cancer with several tumor markers in patients with colorectal disease.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Oncology; 2004; 66(4):296-302. PubMed ID: 15218297
[TBL] [Abstract][Full Text] [Related]
34. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
35. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
36. [Standards, options and recommendations for tumor markers in colorectal cancer].
Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of the tumor markers CEA and CA 19-9 in colorectal diagnosis].
Heptner G; Domschke S; Krapf F; Schneider MU; Iro H; Domschke W
Dtsch Med Wochenschr; 1984 Aug; 109(35):1309-12. PubMed ID: 6590287
[TBL] [Abstract][Full Text] [Related]
38. [Arginase as a marker of cancerogenesis. III. Comparison of arginase activity with CEA and Ca 19-9 in liver metastases of colorectal cancer].
Porembska Z; Skwarek A; Chrzanowska A; Mielczarek M; Nyckowski P; Barańczyk-Kuźma A
Pol Merkur Lekarski; 2004 Jan; 16(91):31-3. PubMed ID: 15074017
[TBL] [Abstract][Full Text] [Related]
39. Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma.
Forslund A; Engarås B; Lönnroth C; Lundholm K
Int J Oncol; 2002 May; 20(5):1013-8. PubMed ID: 11956598
[TBL] [Abstract][Full Text] [Related]
40. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]